These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9293422)

  • 1. Antihypertensive therapy in patients with diabetic nephropathy.
    Mehler PS; Schrier RW
    Kidney Blood Press Res; 1997; 20(2):74-81. PubMed ID: 9293422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus.
    Mogensen CE; Petersen MM; Hansen KW; Christensen CK
    J Hypertens Suppl; 1992 Apr; 10(1):S43-51. PubMed ID: 1619502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT).
    Diabetes; 2001 Apr; 50(4):843-50. PubMed ID: 11289051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors.
    Cooper ME; Rumble JR; Gin T; Lim-Joon T
    Clin Exp Pharmacol Physiol Suppl; 1992; 19():23-7. PubMed ID: 1395113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and diabetic nephropathy.
    Mehler PS; Schrier RW
    Curr Hypertens Rep; 1999; 1(2):170-7. PubMed ID: 10981062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure reduction as a preventive treatment of diabetic nephropathy.
    Ribstein J; Mimran A
    Clin Invest Med; 1991 Dec; 14(6):661-70. PubMed ID: 1794216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria.
    Donnelly R; Molyneaux LM; Willey KA; Yue DK
    Am J Cardiol; 1996 Feb; 77(6):26B-30B. PubMed ID: 8848991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive therapy and diabetic microvascular disease.
    Cooper ME
    Clin Exp Hypertens; 1997; 19(5-6):769-78. PubMed ID: 9247754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection in diabetes: an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
    Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
    Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Tsalamandris C; Cooper ME
    Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
    Yokoyama H; Tomonaga O; Hirayama M; Ishii A; Takeda M; Babazono T; Ujihara U; Takahashi C; Omori Y
    Diabetologia; 1997 Apr; 40(4):405-11. PubMed ID: 9112017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue?
    Laverman GD; Bakker SJ; Navis GJ
    Diabetologia; 2009 Jun; 52(6):1217-8. PubMed ID: 19294362
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.